CALL/NOVO-NORDISK B/1400/0.01/19.12.25 | Market Closed - BOERSE MUENCHEN 19:26:06 17/05/2024 BST | ||
| 0.063 EUR | +1.61% |
|
| Current month | -7.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.063 | +1.61% |
| 16/05/24 | 0.062 | +5.08% |
| 15/05/24 | 0.059 | +3.51% |
| 14/05/24 | 0.057 | -3.39% |
| 13/05/24 | 0.059 | +11.32% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 07:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG7D9T |
| ISIN | DE000GG7D9T9 |
| Date issued | 22/04/2024 |
| Strike | 1,400 kr |
| Maturity | 19/12/2025 (580 Days) |
| Parity | 100 : 1 |
| Emission price | 0.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.068 € |
|---|---|
| Lowest since issue | 0.049 € |
| Spread | 0.05 € |
| Spread % | 45.45% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Warrants
- Warrant
